-
- Zanamivir
- Oseltamivir
- Amantadine
- Rimantadine
- Others
- Interferons
- Vaccines
- Trivalent
- Quadrivalent
The U.S. Influenza Market was valued at US$ 2.7 billion in 2021 and is expected to witness a CAGR of 16.2% over the forecast period 2022–2028 Influenza is an upper respiratory tract disease and is caused by the influenza virus. U.S. Influenza Market is mainly three types namely Influenza A, Influenza B, and Influenza C. Influenza is a communicable disease, spread through a flu cough, droplets from the infected people, sneeze or talks. The common symptoms occur in influenza patients are chills, cough, running nose, sore throat, body aches, headache, fatigue, some cases people may have vomiting and diarrhea. The complication of the disease may include ear infections, bacterial pneumonia, dehydration, sinus infections, and sometimes it leads to congestive heart failure, and asthma. Influenza commonly occurs in geriatric population and children with less than 5 years of age.  The infection may be confirmed by testing the sputum, nose, or throat for the virus. A number of rapid tests are available however polymerase chain reaction that detects the virus's RNA is more accurate. Influenza vaccines are key revenue contributor for the growth of U.S. influenza market. The U.S. influenza market is in growing phase, several international players are actively involved in the development of vaccines and drugs to treat influenza. The launch of new products, technological innovations, and approvals from U.S. Food and Drug Administration (FDA) for various drugs might fuel the growth of U.S. influenza market. For instance, Squires used both egg and cell-based technologies to offer the broadcast portfolio of influenza vaccines in the U.S. for both trivalent and quadrivalent formulations. Similarly, transformative changes in other vaccine markets, due to the entrance of expensive and innovative vaccines such as Gardasil (Merck) and Bexsero (GSK) are projected to contribute growth of the U.S. influenza market. In May 2016, Seqirus received approval from U.S. Food and Drug Administration for Flucelvax Quadrivalent, that was the first U.S. licensed cell-based quadrivalent influenza vaccine indicated for people aged four years and older. In November 2016, GSK received approval from U.S. Food and Drug Administration for flulaval Quadrivalent to include use in children aged six months or older
U S Influenza Market Summary
Study Period
2023-29
Base Year
2022
CAGR
16.2%
Largest Market
U.S
Fastest Growing Market
N/A
U.S. Influenza Market Dynamics
The U.S. Influenza market is growing at a significant CAGR due to rise in newborn babies, an increase in geriatric population. Increase in vaccination awareness, favorable reimbursement scenario, and rising investment by companies in research and development activities are the major factors fuelling the growth of U.S. influenza market over the forecast period. The major market players have great pipeline products, initiatives by government bodies such as WHO and CDC to control and prevent influenza, technological advancements in diagnostic tests also fuel the growth of U.S. influenza market over the forecast period. However, limited production capacity, a high level of required investment, and stringent regulatory policies for new product approvals might hamper the growth of U.S. Influenza market. Due to limitations in current technologies, the lengthy production times (approximately seven months), increase in prices of influenza diagnostic kits and reagents also hinder the U.S. Influenza market.
U S Influenza Market Regional Analysis
North-America Got Significant Share
U.S. holds a dominant share in the global influenza market. The largest share is attributed to the higher rate of in-vitro diagnostics availability and technological advancements in medical devices which are primarily driving the U.S. Influenza market growth. As per CDC, persons above 6 months of age could be vaccinated to prevent the influenza infection. Increase in prevalence and incidence cases of influenza (According to CDC, about 5 to 20 percent of the U.S. people are infected with influenza in every year. CDC also states that about 200,000 people hospitalized and more than 36,000 people are dying from influenza in U.S) might increase the growth of U.S. influenza market. Similarly, the upsurge in funding by the government is also driving the market growth in the United States. The U.S. government awarded 5-year contracts for more than US$ 1 Bn to five drug manufacturers developing technology for speedier mass production of influenza vaccines
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
U S Influenza Market Segmentation
Drug Class,
Route of Administrat
- Oral
- Parenteral
- Others
Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Others
Frequently Asked Questions
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
- Executive summary
- U.S. Influenza Market Introduction
- U.S. Influenza Market Dynamics
- U.S. Influenza Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
- U.S. Influenza Market, By Drug Class, 2015 – 2019 and Forecast, 2020 – 2026
- U.S. Influenza Market Forecast, By Route of Administration, 2015 – 2019 and Forecast, 2020 – 2026
- U.S. Influenza Market Forecast, By Distribution Channel, 2015 – 2019 and Forecast, 2020 – 2026
- U.S. Influenza Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
- Competition Landscape
- Research Methodology
- Key Assumptions and Acronyms
- AstraZeneca (U.K.)
- F. Hoffmann-La Roche (Switzerland)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Sanofi (France)
- Seqirus (U.K.)
- Protein Sciences Corporation (U.S.)
- Emergent Biosolutions (U.S.)
- BioCryst Pharmaceuticals.Inc (U.S.)
- Alvogen (South Korea)
- Medimmune Inc. (U.S.)
- DynPort Vaccine Company, LLC. (U.S.)
- Abbott Laboratories (U.S.)